Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

ST5 Positively Regulates Osteoclastogenesis via Src/Syk/calcium Signaling Pathways.

Kim MK, Kim B, Kwon JO, Song MK, Jung S, Lee ZH, Kim HH.

Mol Cells. 2019 Nov 30;42(11):810-819. doi: 10.14348/molcells.2019.0189.

2.

Serum calcium-decreasing factor, caldecrin, inhibits receptor activator of NF-κB ligand (RANKL)-mediated Ca2+ signaling and actin ring formation in mature osteoclasts via suppression of Src signaling pathway.

Tomomura M, Hasegawa H, Suda N, Sakagami H, Tomomura A.

J Biol Chem. 2012 May 25;287(22):17963-74. doi: 10.1074/jbc.M112.358796. Epub 2012 Mar 29.

3.

The dectin 1 agonist curdlan regulates osteoclastogenesis by inhibiting nuclear factor of activated T cells cytoplasmic 1 (NFATc1) through Syk kinase.

Yamasaki T, Ariyoshi W, Okinaga T, Adachi Y, Hosokawa R, Mochizuki S, Sakurai K, Nishihara T.

J Biol Chem. 2014 Jul 4;289(27):19191-203. doi: 10.1074/jbc.M114.551416. Epub 2014 May 12.

5.

Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.

Hasegawa H, Kido S, Tomomura M, Fujimoto K, Ohi M, Kiyomura M, Kanegae H, Inaba A, Sakagami H, Tomomura A.

J Biol Chem. 2010 Aug 13;285(33):25448-57. doi: 10.1074/jbc.M109.068742. Epub 2010 Jun 14.

6.

MKP-1 signaling events are required for early osteoclastogenesis in lineage defined progenitor populations by disrupting RANKL-induced NFATc1 nuclear translocation.

Valerio MS, Herbert BA, Griffin AC 3rd, Wan Z, Hill EG, Kirkwood KL.

Bone. 2014 Mar;60:16-25. doi: 10.1016/j.bone.2013.11.012. Epub 2013 Nov 20.

7.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
8.

Alternative NF-κB Regulates RANKL-Induced Osteoclast Differentiation and Mitochondrial Biogenesis via Independent Mechanisms.

Zeng R, Faccio R, Novack DV.

J Bone Miner Res. 2015 Dec;30(12):2287-99. doi: 10.1002/jbmr.2584. Epub 2015 Aug 6.

9.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

10.

Tetrandrine attenuates the bone erosion in collagen-induced arthritis rats by inhibiting osteoclastogenesis via spleen tyrosine kinase.

Jia Y, Miao Y, Yue M, Shu M, Wei Z, Dai Y.

FASEB J. 2018 Jun;32(6):3398-3410. doi: 10.1096/fj.201701148RR. Epub 2018 Jan 30.

PMID:
29401630
11.

Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.

Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.

Bone. 2007 Oct;41(4):592-602. Epub 2007 Jun 13.

PMID:
17627913
12.

Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.

Kang MR, Jo SA, Yoon YD, Park KH, Oh SJ, Yun J, Lee CW, Nam KH, Kim Y, Han SB, Yu J, Rho J, Kang JS.

Mar Drugs. 2014 Nov 24;12(11):5643-56. doi: 10.3390/md12115643.

13.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

14.

SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion.

Zhou Y, Mohan A, Moore DC, Lin L, Zhou FL, Cao J, Wu Q, Qin YX, Reginato AM, Ehrlich MG, Yang W.

FASEB J. 2015 May;29(5):1635-45. doi: 10.1096/fj.14-260844. Epub 2015 Jan 15.

15.

Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.

Joung YH, Darvin P, Kang DY, Sp N, Byun HJ, Lee CH, Lee HK, Yang YM.

PLoS One. 2016 Jul 22;11(7):e0159891. doi: 10.1371/journal.pone.0159891. eCollection 2016.

16.

Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.

Koide N, Kondo Y, Odkhuu E, Ulziisaikhan J, Ukaji T, Yokochi T, Umezawa K.

Immunol Lett. 2014 Sep;161(1):31-7. doi: 10.1016/j.imlet.2014.04.006. Epub 2014 May 2.

PMID:
24792671
17.

Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.

Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.

Biochem Biophys Res Commun. 2005 Apr 15;329(3):839-45.

PMID:
15752732
18.

Homer2 and Homer3 modulate RANKL-induced NFATc1 signaling in osteoclastogenesis and bone metabolism.

Son A, Kang N, Oh SY, Kim KW, Muallem S, Yang YM, Shin DM.

J Endocrinol. 2019 Jul 1. pii: JOE-19-0123.R1. doi: 10.1530/JOE-19-0123. [Epub ahead of print]

PMID:
31319381
19.

IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1).

Chen Z, Su L, Xu Q, Katz J, Michalek SM, Fan M, Feng X, Zhang P.

J Biol Chem. 2015 Dec 11;290(50):30163-74. doi: 10.1074/jbc.M115.663518. Epub 2015 Oct 19.

20.

Supplemental Content

Support Center